Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia

Chuan-Tsai Tsai; Yi-Hsin Chan; Jo-Nan Liao; Tzeng-Ji Chen; Gregory Y. H. Lip; Shih-Ann Chen; Tze-Fan Chao

doi:10.1055/a-2184-7506

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2024; 124(03): 253-262
DOI: 10.1055/a-2184-7506

Stroke, Systemic or Venous Thromboembolism

Risk of Incident Atrial Fibrillation and Subsequent Use of Oral Anticoagulants in Patients with Dementia

Chuan-Tsai Tsai^*

¹Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

²Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

,

Yi-Hsin Chan^*

³The Cardiovascular Department, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

⁴College of Medicine, Chang Gung University, Taoyuan, Taiwan

⁵Microscopy Core Laboratory, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan

,

Jo-Nan Liao

¹Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

²Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

,

Tzeng-Ji Chen

⁶Department of Family Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

,

Gregory Y. H. Lip^**

⁷Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart and Chest Hospital, Liverpool, United Kingdom and Danish Center for Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

,

Shih-Ann Chen^**

¹Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

²Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

⁸Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan

,

Tze-Fan Chao

¹Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan

²Institute of Clinical Medicine and Cardiovascular Research Center, National Yang Ming Chiao Tung University, Taipei, Taiwan

› Institutsangaben

Abstract

Background Dementia and atrial fibrillation (AF) have many shared risk factors. Besides, patients with dementia are under-represented in randomized trials, and even if AF is present, oral anticoagulants (OACs) are not prescribed frequently. This study aimed to report the incidence of newly diagnosed AF in dementia patients, and the impacts of use of vitamin K antagonist (VKA; e.g., warfarin) and non-VKA OAC (NOACs) on stroke and bleeding outcomes.

Methods Our study utilized the Taiwan National Health Insurance Research Database. A total of 554,074 patients with dementia were compared with 554,074 age- and sex-matched patients without dementia regarding the risk of incident AF. Among patients with dementia who experienced incident AF, the risks of clinical events of patients treated with warfarin or NOACs were compared with those without OACs (reference group).

Results The risk of incident AF was greater for patients with dementia compared with those without (adjusted hazard ratio [aHR]: 1.054; 95% confidence interval [CI]: 1.040–1.068 for all types of dementia, aHR: 1.035; 95% CI: 1.020–1.051 for presenile/senile dementia, and aHR: 1.125; 95% CI: 1.091–1.159 for vascular dementia). Among patients with dementia and experienced incident AF, warfarin use was associated with a higher risk of ischemic stroke (aHR: 1.290; 95% CI: 1.156–1.440), intracranial hemorrhage (ICH; aHR: 1.678; 95% CI: 1.346–2.090), and major bleeding (aHR: 1.192; 95% CI: 1.073–1.323) compared with non-OACs. NOAC use was associated with a lower risk of ischemic stroke (aHR: 0.421; 95% CI: 0.352–0.503) and composite risk of ischemic stroke or major bleeding (aHR: 0.544; 95% CI: 0.487–0.608) compared with non-OACs. These results were consistent among the patients after the propensity matching.

Conclusion In this large nationwide cohort, the risk of newly diagnosed AF was higher in patients with dementia (all dementia, presenile/senile dementia, and vascular dementia) compared with those without dementia. For patients with dementia who experienced incident AF, NOAC use was associated with a better clinical outcome compared with non-OAC. Patients with dementia require a holistic approach to their care and management, including the use of NOACs to reduce the risks of clinical events.

Keywords

atrial fibrillation - dementia - NOACs

Volltext

Referenzen

References
1 Blum S, Conen D. Mechanisms and clinical manifestations of cognitive decline in atrial fibrillation patients: potential implications for preventing dementia. Can J Cardiol 2023; 39 (02) 159-171
2 Garcia-Ptacek S, Kåreholt I, Cermakova P, Rizzuto D, Religa D, Eriksdotter M. Causes of death according to death certificates in individuals with dementia: a cohort from the Swedish Dementia Registry. J Am Geriatr Soc 2016; 64 (11) e137-e142
3 Dodson JA, Petrone A, Gagnon DR, Tinetti ME, Krumholz HM, Gaziano JM. Incidence and determinants of traumatic intracranial bleeding among older veterans receiving warfarin for atrial fibrillation. JAMA Cardiol 2016; 1 (01) 65-72
4 Rivard L, Friberg L, Conen D. et al. Atrial fibrillation and dementia: a report from the AF-SCREEN International Collaboration. Circulation 2022; 145 (05) 392-409
5 Caramelli B, Yu PC, Cardozo FAM. et al. Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial. BMC Med 2022; 20 (01) 374
6 Søgaard M, Skjøth F, Jensen M. et al. Nonvitamin K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients and risk of dementia: a nationwide propensity-weighted cohort study. J Am Heart Assoc 2019; 8 (11) e011358
7 Cheng WH, Chiang CE, Lin YJ. et al. Non-vitamin K antagonist oral anticoagulants in elderly (≥85 years) patients with newly diagnosed atrial fibrillation: changing clinical practice and outcomes for stroke prevention in a nationwide cohort study. Mayo Clin Proc 2021; 96 (01) 52-65
8 Chao TF, Chiang CE, Chan YH. et al. Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm 2021; 18 (06) 871-877
9 Chao TF, Chan YH, Chiang CE. et al. Continuation or discontinuation of oral anticoagulants after HAS-BLED scores increase in patients with atrial fibrillation. Clin Res Cardiol 2022; 111 (01) 23-33
10 Chao TF, Chan YH, Tuan TC. et al. Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study. Eur Heart J Qual Care Clin Outcomes 2022; 8 (05) 588-595
11 Liao JN, Lim SS, Chen TJ, Tuan TC, Chen SA, Chao TF. Modified Taiwan Atrial Fibrillation Score for the prediction of incident atrial fibrillation. Front Cardiovasc Med 2022; 8: 805399
12 Chao TF, Chan YH, Chiang CE. et al. Stroke prevention with direct oral anticoagulants in high-risk elderly atrial fibrillation patients at increased bleeding risk. Eur Heart J Qual Care Clin Outcomes 2022; 8 (07) 730-738
13 Chao TF, Chiang CE, Chen TJ, Liao JN, Tuan TC, Chen SA. Clinical risk score for the prediction of incident atrial fibrillation: derivation in 7 220 654 taiwan patients with 438 930 incident atrial fibrillations during a 16-year follow-up. J Am Heart Assoc 2021; 10 (17) e020194
14 Chao TF, Chan YH, Chiang CE. et al. Early rhythm control and the risks of ischemic stroke, heart failure, mortality, and adverse events when performed early (<3 months): a nationwide cohort study of newly diagnosed patients with atrial fibrillation. Thromb Haemost 2022; 122 (11) 1899-1910
15 Chao TF, Lip GYH, Lin YJ. et al. Major bleeding and intracranial hemorrhage risk prediction in patients with atrial fibrillation: attention to modifiable bleeding risk factors or use of a bleeding risk stratification score? A nationwide cohort study. Int J Cardiol 2018; 254: 157-161
16 Tsai CT, Liao JN, Chiang CE. et al. Association of ischemic stroke, major bleeding, and other adverse events with warfarin use vs non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation with a history of intracranial hemorrhage. JAMA Netw Open 2020; 3 (06) e206424
17 Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiol Drug Saf 2011; 20 (03) 236-242
18 Hsieh CY, Chen CH, Li CY, Lai ML. Validating the diagnosis of acute ischemic stroke in a National Health Insurance claims database. J Formos Med Assoc 2015; 114 (03) 254-259
19 Dagres N, Chao TF, Fenelon G. et al; ESC Scientific Document Group. European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) expert consensus on arrhythmias and cognitive function: what is the best practice?. Europace 2018; 20 (09) 1399-1421
20 Dietzel J, Haeusler KG, Endres M. Does atrial fibrillation cause cognitive decline and dementia?. Europace 2018; 20 (03) 408-419
21 Gardarsdottir M, Sigurdsson S, Aspelund T. et al. Improved brain perfusion after electrical cardioversion of atrial fibrillation. Europace 2020; 22 (04) 530-537
22 Kim D, Yang PS, Yu HT. et al. Risk of dementia in stroke-free patients diagnosed with atrial fibrillation: data from a population-based cohort. Eur Heart J 2019; 40 (28) 2313-2323
23 Wang K, Lu Y, Simegn MA, Xue H, Asinger RW. Use of SAMe-TT(2)R(2) in a racially diverse anticoagulation clinic: prediction of optimal anticoagulation. J Thromb Thrombolysis 2023; 55 (01) 175-180
24 Chan YH, Lee KT, Kao YW. et al. The comparison of non-vitamin K antagonist oral anticoagulants versus well-managed warfarin with a lower INR target of 1.5 to 2.5 in Asians patients with non-valvular atrial fibrillation. PLoS One 2019; 14 (03) e0213517
25 Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol 2017; 14 (11) 627-628
26 Schnabel RB, Marinelli EA, Arbelo E. et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace 2023; 25 (01) 6-27
27 Romiti GF, Pastori D, Rivera-Caravaca JM. et al. Adherence to the ‘Atrial Fibrillation Better Care’ pathway in patients with atrial fibrillation: impact on clinical outcomes-a systematic review and meta-analysis of 285,000 patients. Thromb Haemost 2022; 122 (03) 406-414
28 Hindricks G, Potpara T, Dagres N. et al; ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (05) 373-498
29 Gorog DA, Gue YX, Chao TF. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific Expert Consensus Paper. Thromb Haemost 2022; 122 (10) 1625-1652
30 Chang CH, Lee YC, Tsai CT. et al. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease. Atherosclerosis 2014; 232 (01) 224-230

Zusatzmaterial

Supplementary Material